Windward Bio Group AG is a clinical-stage biopharmaceutical company focused on the discovery, licensing, and clinical development of differentiated, ultra-long-acting biologic therapeutics targeting clinically validated immunological pathways. The company operates primarily from Basel, Switzerland, with corporate operations also established in the United States, and holds commercialization rights to its clinical-stage assets outside Greater China. Windward Bio operates in a single operating segment focused on research and drug development and is pre-revenue, having generated no commercial product sales since inception. Its pipeline is anchored by two primary clinical assets: WIN378, an ultra-long-acting fully human monoclonal antibody designed to inhibit TSLP, currently being evaluated in a Phase 2/3 study (POLARIS-1) for severe uncontrolled asthma and a Phase 2 study (SIRIUS) for COPD with a target twice-yearly subcutaneous dosing regimen; and WIN027, an investigational long-acting bispecific antibody designed to neutralize both TSLP and IL-13 simultaneously, undergoing Phase 1 evaluation with planned Phase 2 studies in COPD and atopic dermatitis. The company also maintains internal discovery research to feed its pipeline of bispecific antibodies. Windward Bio targets substantial therapeutic markets including severe asthma, COPD, and atopic dermatitis, competing against approved biologic standards of care such as tezepelumab (Tezspire) and dupilumab (Dupixent). Its competitive positioning centers on optimized molecular design aimed at substantially longer dosing intervals (e.g., semi-annual subcutaneous injections) and dual-pathway cytokine inhibition, designed to improve real-world treatment adherence and disease control.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!